null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.51x Total Debt / Equity (Moderate leverage)

A 200bps rate rise adds ~$40-50M annual interest expense given ~$2.8B floating-rate debt; meaningful but manageable at ~4-5% of EBITDA

Medium intensity; US-China trade tariffs on metals and components disrupt supply chains.

China (research model sourcing, particularly NHP primates) and India (biologics/CDMO inputs); NHP export restrictions post-2023 materially disrupted supply

EUR (~30% of revenue), GBP (~10%), CNY (~5%) exposure; EUR/USD and GBP/USD volatility creates ~3-5% revenue translation risk annually

Operations in 20+ countries; top FX exposures are EUR, GBP, CNY — EUR devaluation of 10% would reduce reported revenue by ~$90-100M

Medium intensity; commodities: Steel, Aluminum, Copper, Crude Oil (fuel), Rare Earth Elements, Plastics/Resins; geopolitical: US-China trade tariffs on metals and components disrupt supply chains.

No single vendor exceeds 30% of input costs, but NHP suppliers (Mauritius, China) represent a near-non-substitutable biological input for safety testing

On-premise lab and vivarium infrastructure dominates; cloud disruption would affect informatics/DSA platforms but not core wet-lab operations — moderate 30-day disruption risk

SaaS-adjacent safety assessment data platforms (Instem, Labcorp comparables); cloud termination would impair data delivery but not biological testing revenue

API coupling risk is low-moderate; proprietary LIMS and study management systems create moderate lock-in but are not deeply API-integrated with external platforms

Fails Howey Test entirely; revenue is fee-for-service contract research — no investment contract, no profit expectation from others' efforts; Howey risk = negligible

Medium

High GDPR exposure: processes human-adjacent biological and clinical data across EU; CCPA applies to California operations; dedicated compliance infrastructure required and in place

Moderate-high; CRL holds ~25-30% share of global CRO/preclinical market; FTC blocked Covance merger historically; future large acquisitions face scrutiny

Medium burden; regimes: FAA, DOT, OSHA, EPA, ITAR, FTC; Export controls and defense procurement rules create contract concentration risk.

~60-65% recurring via multi-year Master Service Agreements and retainer-based DSA contracts; ~35-40% transactional project-based study work

Fee-for-service study execution (primary), long-term DSA retainer contracts (secondary), research model sales (tertiary); services represent ~85% of total revenue

Cost-plus with utilization-based pricing; inflation pass-through is partial (~60-70%); NHP price spikes ($25K+ per animal) compress margins when contracts are fixed-price

7/10; regulated drug development timelines create captive demand, but large pharma clients negotiate multi-year volume discounts limiting upside pricing power

7.5% Gross Margin (Thin (<20%))

No free-rider problem; services are proprietary and billable. Key risk is pharma R&D budget cuts causing program deferrals — churn vulnerability moderate at ~10-15% annually

Revenue growth is headcount-linear to sublinear; lab technicians and study directors scale with volume but automation and platform leverage allow ~1.5x revenue per incremental headcount

Moderately capital and labor intensive; doubling revenue requires ~70-80% headcount increase and significant vivarium/facility capex — not a software-like marginal cost curve

Not a franchise model; N/A — but GLP/GMP regulatory compliance across 60+ sites represents analogous drift risk; FDA/EMA audit findings are a material operational risk

At 10x scale, CAC economics improve via enterprise account penetration; current blended CAC likely $50-200K per pharma account with LTV of $5-50M — strong LTV/CAC ratio

Weak direct network effects; proprietary historical safety databases and reference ranges create data moats but not true network effects — durability based on switching costs not virality

-1.4% Return on Assets (Negative equity)

Tier 2 resilience; early-stage biotech clients cut budgets in downturns (2022-2023 proven), but large pharma pipelines provide base stability — not fully recession-proof

Large pharmaceutical and biotechnology companies (~70% of revenue); top 20 pharma clients represent ~40-50% of revenue — moderate concentration risk

Emerging biotechs, academic/government research institutions (~20-25% of revenue); highly sensitive to NIH funding and VC biotech investment cycles

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "23-0000 Legal Occupations", "33-0000 Protective Service Occupations", "37-0000 Building and Grounds Cleaning and Maintenance Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "47-0000 Construction and Extraction Occupations", "49-0000 Installation, Maintenance, and Repair Occupations", "51-0000 Production Occupations", "53-0000 Transportation and Material Moving Occupations"]

0.3 (HIL — ~30% of characteristic roles agent-automatable)

Capex ~5-7% of revenue; capital allocation shifting toward automation, digital pathology, and in vitro platforms from legacy NHP-dependent vivarium infrastructure — transitional reallocation underway

0001100682

CRL